The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling ; volume:22 ; number:1 ; day:12 ; month:3 ; year:2024 ; pages:1-18 ; date:12.2024
Cell communication and signaling ; 22, Heft 1 (12.3.2024), 1-18, 12.2024
- Urheber
-
Li, Tianye
Niu, Mengke
Zhou, Jianwei
Wu, Kongming
Yi, Ming
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12964-024-01562-5
- URN
-
urn:nbn:de:101:1-2405150828198.073700110133
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:46 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Li, Tianye
- Niu, Mengke
- Zhou, Jianwei
- Wu, Kongming
- Yi, Ming
- SpringerLink (Online service)
Ähnliche Objekte (12)
A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Correction: A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity
PD-L1 siRNA hitched polyethyleneimine-elastase constituting nanovesicle induces tumor immunogenicity and PD-L1 silencing for synergistic antitumor immunotherapy
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
The expression of PD-L1 on tumor-derived exosomes enhances infiltration and anti-tumor activity of αCD3 × αPD-L1 bispecific antibody-armed T cells
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
Zosuquidar Promotes Antitumor Immunity by Inducing Autophagic Degradation of PD‐L1
Regulatory mechanisms of PD-1/PD-L1 in cancers
PD-1/PD-L1 binding studies using microscale thermophoresis
The PD-1:PD-L1 axis in Inflammatory Arthritis
A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Correction: A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity
PD-L1 siRNA hitched polyethyleneimine-elastase constituting nanovesicle induces tumor immunogenicity and PD-L1 silencing for synergistic antitumor immunotherapy
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
The expression of PD-L1 on tumor-derived exosomes enhances infiltration and anti-tumor activity of αCD3 × αPD-L1 bispecific antibody-armed T cells
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
Zosuquidar Promotes Antitumor Immunity by Inducing Autophagic Degradation of PD‐L1
Regulatory mechanisms of PD-1/PD-L1 in cancers
PD-1/PD-L1 binding studies using microscale thermophoresis
The PD-1:PD-L1 axis in Inflammatory Arthritis
A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Correction: A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity
PD-L1 siRNA hitched polyethyleneimine-elastase constituting nanovesicle induces tumor immunogenicity and PD-L1 silencing for synergistic antitumor immunotherapy
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
The expression of PD-L1 on tumor-derived exosomes enhances infiltration and anti-tumor activity of αCD3 × αPD-L1 bispecific antibody-armed T cells
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
Zosuquidar Promotes Antitumor Immunity by Inducing Autophagic Degradation of PD‐L1
Regulatory mechanisms of PD-1/PD-L1 in cancers
PD-1/PD-L1 binding studies using microscale thermophoresis